Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients : An Italian real-life experience
© 2024 The Authors..
Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment.
Design and methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot.
Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = - 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R2 = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of -25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results.
Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Practical laboratory medicine - 39(2024) vom: 10. März, Seite e00392 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Romano, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.plabm.2024.e00392 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371069173 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371069173 | ||
| 003 | DE-627 | ||
| 005 | 20240425234554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.plabm.2024.e00392 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM371069173 | ||
| 035 | |a (NLM)38617587 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Romano, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients |b An Italian real-life experience |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment | ||
| 520 | |a Design and methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot | ||
| 520 | |a Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = - 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R2 = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of -25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results | ||
| 520 | |a Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ECLIA | |
| 650 | 4 | |a ELISA | |
| 650 | 4 | |a Interleukin-6 | |
| 700 | 1 | |a Lanzilao, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Edda |e verfasserin |4 aut | |
| 700 | 1 | |a Infantino, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Nencini, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Cappelli, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Dugheri, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Manfredi, Mariangela |e verfasserin |4 aut | |
| 700 | 1 | |a Fanelli, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Amedei, Amedeo |e verfasserin |4 aut | |
| 700 | 1 | |a Mucci, Nicola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Practical laboratory medicine |d 2015 |g 39(2024) vom: 10. März, Seite e00392 |w (DE-627)NLM275285375 |x 2352-5517 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g day:10 |g month:03 |g pages:e00392 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.plabm.2024.e00392 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |b 10 |c 03 |h e00392 | ||